FDA Approvals for 4th Quarter of 2015
Recently, the following drugs have received approved by the FDA:
Gilead Sciences received approval in November for Genvoya in the treatment of HIV-1 infection.
Those needing management of osteoarthritis pain now have another option in Vivlodex from Iroko Pharmaceuticals.
Aristada from Alkermes received approval for the treatment of schizophrenia.
Those suffering from severe pain may find relief in Belbuca from Endo Pharmaceuticals.
Several new cancer treatments are now available:
Alecensa from Roche has been approved for the treatment of ALK-positive, metastatic non-small cell lung cancer.
Cotellic from Genentech was approved in November for the treatment of BRAF V600E or V600K melanoma.
Janssen Biotech has received approval for Darzalex for the treatment of multiple myeloma.
For the treatment of patients with multiple myeloma who have received prior therapies, Empliciti from Bristol-Myers Squibb has been approved.
Imlygic from Amgen has been approved for the treatment of unresectable recurrent melanoma.
Millennium Pharmaceuticals has been approved for Ninlaro for the treatment of multiple myeloma.
Onivyde from Merrimack has been approved for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy.
A new treatment for metastatic squamous non-small cell lung cancer has been approved: Portrazza from Eli Lilly.
AstraZeneca has been approved for Tagrisso for the treatment of EGFR T790M mutation positive non-small cell lung cancer.
Those suffering from liposarcoma or leiomyosarcoma be find relief in Yondelis by Janssen which as approved in October.
Two new treatments for those with lung disease are now available:
Nucala from GlaxoSmithKline has been approved for the treatment of severe asthma with an eosinophilic phenotype.
For the long-term maintenance treatment of airflow obstruction in patients with COPD, Utibron Neohaler from Novartis has been approved.
For more information about these new medications, talk to your doctor for pharmacist to find out more.